Loading page content…
Loading page content…
| Source: | Find a Tender Service (FTS) |
| Buyer: | MEDICINES DISCOVERY CATAPULT LIMITED |
| Main Category: | Services |
| Procurement Method: | Open procedure |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | £300,000 |
| Estimated Value (inc. VAT): | £360,000 |
| Release Date: | 12 November 2025 |
| Application Deadline: | 9 December 2025 |
| Enquiry Deadline: | 26 November 2025 |
| Contract Start Date: | 9 February 2026 (Estimated) |
| Contract End Date: | 8 August 2027 (Estimated) |
| Contract Duration: | 1.5 years |
| Procurement ID (OCID): | ocds-h6vhtk-05df7e |
| Notice Reference: | 073142-2025 |
View Original Notice
Access the full notice on the official portal
PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. The PACE programme is looking for an external provider to deliver an 'Enabling Project' in partnership related to early health economic analysis to support our cohort of AMR diagnostic innovation developers from our 2nd PACE funding call. Please see (https://paceamr.org.uk/news/ukhsa-announced-as-first-pace-collaboration-to-help-tackle-deadly-antimicrobial-resistance/) for details of our first enabling project partnering with UKHSA to provide access to clinical isolates for our first cohort of therapeutics developers. The overall purpose of this second enabling project is to provide PACE awardees and the wider AMR community with access to practical early-stage health economic outputs, including care pathway insights, indicative cost analyses, early-stage economic modelling and value proposition frameworks tailored to our cohorts emerging diagnostic technologies. These outputs will be designed to support product development decisions, stakeholder engagements and future reimbursement planning with relevance across bloodstream infections (BSI), respiratory tract infections (RTI) and urinary tract infections (UTI). To maximise impact, the provider is expected to group diagnostics with similar clinical positioning or use cases together to make the most of synergies across the cohort (e.g. when establishing the existing care pathway of the indications). Where relevant, the provider is also expected to align with existing or ongoing initiatives. A key priority is to ensure that insights, and findings from the project are made publicly available through open-access tools, share reports etc. to ensure that it benefits the broader AMR innovation community to inform future policy, funding and procurement decisions. The support required is across three work packages: Kick-off webinar: Introduce PACE awardees (diagnostics projects) to early-stage health economic assessment including its purpose, relevance and application across the cohort. Baseline development and modelling tool: Deliver care-pathway analyses (BSI, RTI and UTI) and a re-usable (modelling with guidance -enabling scenario testing using default assumptions. Project-specific deployment: Collaborate with each PACE project to input diagnostic specific data, generate tailored analyses, and refine the tool using real-world examples.
Document pack· 1 file
Published contracts in the last 12 months
39
total contracts
£5.8m
total value
£524,999
average contract size
Typical categories
Pipeline status
Not addedContract imported automatically · AI writes the response
Application Deadline
9 December 2025
Closed
Estimated Value
£300,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →